The Pancreatic Cyst Dilemma: Why ‘Watchful Waiting’ Is So Hard
-
Click here to listen to this article - Share via
Key Facts:
- Pancreatic cysts are increasingly found incidentally due to better imaging technology.
- The primary goal is to distinguish pre-cancerous mucinous cysts (like IPMNs) from benign non-mucinous cysts.
- Guidelines like the Fukuoka and CAPS criteria help stratify risk, but are not perfect.
- High-risk features like mural nodules or a dilated pancreatic duct often prompt surgical consideration.
- Management is a balance between surveillance to avoid overtreatment and surgery to prevent pancreatic cancer.
The Problem of the ‘Incidentaloma’
Another one. The call comes from radiology about a finding on a CT scan done for something totally unrelated—kidney stones, maybe a car accident. “Incidental 2-centimeter cystic lesion in the pancreatic tail.” And so it begins. A decade or two ago, this might have been dismissed. Now, it sets off a cascade of consultations, more imaging, and a lot of anxiety for a person who, five minutes earlier, was perfectly healthy. We are finding these cysts everywhere, a direct result of our imaging getting incredibly good [5][8]. The problem is, our ability to find them has outpaced our ability to know exactly what to do with them.
The central puzzle is sorting the troublemakers from the benign bystanders. Most of these cysts are harmless. But some, particularly the mucin-producing ones, are precursors to pancreatic ductal adenocarcinoma, one of the deadliest cancers we deal with [3][7]. So we’re caught. Do nothing, and we risk missing a chance to prevent a fatal cancer. Intervene on everyone, and we subject a huge number of people to major pancreatic surgery—an operation with serious risks—for a lesion that was never going to hurt them. This is the tightrope we walk.
The first step is always to classify the cyst. Is it making mucus or not? That’s the big question [1]. The ones that don’t, like serous cystadenomas, are almost always benign. We can usually leave those alone. It’s the mucinous ones, like intraductal papillary mucinous neoplasms (IPMNs), that demand our attention. These are the ones with malignant potential. They grow within the ductal system—the pancreas’s plumbing—and can progress. So the entire diagnostic effort is focused on getting a better look, trying to decide which camp a cyst falls into.
Trying to Sharpen the Picture
To get that better look, we have an arsenal of tools. A good MRI can tell us a lot about the cyst’s architecture. But the real deep dive usually comes from an endoscopic ultrasound, or EUS. This lets us get an ultrasound probe right next to the pancreas from inside the stomach, giving us the clearest images possible. And, crucially, it allows us to stick a tiny needle into the cyst and pull out some fluid [3]. Analyzing that fluid for tumor markers like CEA or for specific DNA mutations can give us critical clues about whether it’s a mucinous cyst and if it harbors high-risk changes.
With this information in hand, we turn to guidelines. There are several, but the ones we reference most are the Fukuoka guidelines and the CAPS consortium statements [2]. These are attempts to standardize our approach, to create a flowchart for risk. They give us features to look for. Is the main pancreatic duct dilated? Is there a solid component or a mural nodule—a small growth on the cyst wall? These are what we call “high-risk stigmata” or “worrisome features” [6]. If a patient’s cyst has them, the conversation quickly shifts toward surgery.
But the guidelines aren’t perfect. They’re built on the best data we have, but sometimes they conflict, and studies have shown they have different strengths and weaknesses when it comes to catching advanced disease without flagging too many harmless cysts [4]. One set of rules might be more sensitive, pushing more patients to surgery but missing fewer cancers. Another might be more specific, sparing more people an operation but potentially accepting a slightly higher risk of missing something. There is no magic formula. It always comes back to a judgment call.
The Ground-Level Reality
So what does this all mean in the clinic? It means management is a constant balancing act. For a small cyst with no worrisome features, the answer is usually surveillance. We’ll get another scan in six months or a year, and keep watching it over time [6]. The goal is to see if it grows or develops any of those high-risk features we worry about. For a larger cyst, or one that already has a solid component, the recommendation is often surgery. And for everything in between, it requires a long conversation. A discussion that involves gastroenterologists, radiologists, surgeons, and, most importantly, the patient [2][4][5].
We have to be honest about the limits of our knowledge. We can stratify risk, but we can’t eliminate it. “Watching” a cyst requires a patient to live with a certain level of uncertainty. Opting for surgery means accepting the concrete, upfront risks of a major operation to head off a potential, future risk of cancer. There’s no easy answer.
The science continues to move forward, particularly in molecular diagnostics [9]. The hope is that soon we’ll be able to analyze cyst fluid and say with much greater certainty which ones have the genetic machinery to become cancer. That would be a game-changer. But for now, we operate with the tools we have. We interpret the images, we analyze the fluid, we consult the guidelines, and we talk. It’s a process of shared decision-making, navigating the gray zone between doing too little and doing too much. The “incidentaloma” has made things complicated. Our job is to make them as clear as possible, one patient at a time.
References:
[1] Capurso, G., Rizzo, G. E. M., Coluccio, C., Crinò, S. F., Cucchetti, A., Facciorusso, A., Hassan, C., Amato, A., Auriemma, F., Bertani, H., Binda, C., Cipolletta, F., Forti, E., Fugazza, A., Lisotti, A., Maida, M., Sinagra, E., Sbrancia, M., Spadaccini, M., Tacelli, M., … i-EUS working group (2024). The i-EUS consensus on the management of pancreatic fluid collections - Part 1. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 56(10), 1663–1674. https://doi.org/10.1016/j.dld.2024.06.030
[2] Buerlein, R. C. D., & Shami, V. M. (2021). Management of pancreatic cysts and guidelines: what the gastroenterologist needs to know. Therapeutic advances in gastrointestinal endoscopy, 14, 26317745211045769. https://doi.org/10.1177/26317745211045769
[3] Jani, N., Bani Hani, M., Schulick, R. D., Hruban, R. H., & Cunningham, S. C. (2011). Diagnosis and management of cystic lesions of the pancreas. Diagnostic and therapeutic endoscopy, 2011, 478913. https://doi.org/10.1155/2011/478913
[4] Dbouk, M., Brewer Gutierrez, O. I., Lennon, A. M., Chuidian, M., Shin, E. J., Kamel, I. R., Fishman, E. K., He, J., Burkhart, R. A., Wolfgang, C. L., Hruban, R. H., Goggins, M. G., & Canto, M. I. (2021). Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 21(3), 613–621. https://doi.org/10.1016/j.pan.2021.01.017
[5] Stark, A., Donahue, T. R., Reber, H. A., & Hines, O. J. (2016). Pancreatic Cyst Disease: A Review. JAMA, 315(17), 1882–1893. https://doi.org/10.1001/jama.2016.4690
[6] Lee L. S. (2021). Updates in diagnosis and management of pancreatic cysts. World journal of gastroenterology, 27(34), 5700–5714. https://doi.org/10.3748/wjg.v27.i34.5700
[7] Dreyer, S. B., Beer, P., Hingorani, S. R., & Biankin, A. V. (2025). Improving outcomes of patients with pancreatic cancer. Nature reviews. Clinical oncology, 22(6), 439–456. https://doi.org/10.1038/s41571-025-01019-9
[8] Naudin, S., Wang, M., Dimou, N., Ebrahimi, E., Genkinger, J., Adami, H. O., Albanes, D., Babic, A., Barnett, M., Bogumil, D., Cai, H., Chen, C., Eliassen, A. H., Freudenheim, J. L., Gierach, G., Giovannucci, E. L., Gunter, M. J., Håkansson, N., Hirabayashi, M., Hou, T., … Ferrari, P. (2025). Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America. PLoS medicine, 22(5), e1004590. https://doi.org/10.1371/journal.pmed.1004590
[9] Canakis, A., & Lee, L. S. (2022). State-of-the-Art Update of Pancreatic Cysts. Digestive diseases and sciences, 67(5), 1573–1587. https://doi.org/10.1007/s10620-021-07084-1
